446 related articles for article (PubMed ID: 30482962)
1. Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.
Tang J; Yu JX; Hubbard-Lucey VM; Neftelinov ST; Hodge JP; Lin Y
Nat Rev Drug Discov; 2018 Nov; 17(12):854-855. PubMed ID: 30482962
[No Abstract] [Full Text] [Related]
2. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S; Neftelino ST; Hodge JP; Oliva C; Campbell JR; Yu JX
Nat Rev Drug Discov; 2021 Mar; 20(3):168-169. PubMed ID: 33177720
[No Abstract] [Full Text] [Related]
3. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
5. New checkpoint inhibitors ride the immunotherapy tsunami.
Mullard A
Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
[No Abstract] [Full Text] [Related]
6. Resistance to PD1/PDL1 checkpoint inhibition.
O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ
Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441
[TBL] [Abstract][Full Text] [Related]
7. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
8. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
9. The promise and challenges of immune agonist antibody development in cancer.
Mayes PA; Hance KW; Hoos A
Nat Rev Drug Discov; 2018 Jul; 17(7):509-527. PubMed ID: 29904196
[TBL] [Abstract][Full Text] [Related]
10. Immune agonist antibodies face critical test.
Garber K
Nat Rev Drug Discov; 2020 Jan; 19(1):3-5. PubMed ID: 31907434
[No Abstract] [Full Text] [Related]
11. Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.
Filaci G; Fenoglio D; Taramasso L; Indiveri F; Di Biagio A
Front Immunol; 2018; 9():2447. PubMed ID: 30459765
[TBL] [Abstract][Full Text] [Related]
12. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
[TBL] [Abstract][Full Text] [Related]
13. The immune checkpoint inhibitors: where are we now?
Webster RM
Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
[No Abstract] [Full Text] [Related]
14. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
15. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors: outstanding efficacy but at what cost?
Klastersky JA
Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
[No Abstract] [Full Text] [Related]
17. Efficacy of PD-1 blockade in tumors with MMR deficiency.
Lee V; Le DT
Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
[No Abstract] [Full Text] [Related]
18. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
19. Progress of immune checkpoint therapy in the clinic (Review).
Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibition: new treatment options in urologic cancer.
De Maeseneer DJ; Delafontaine B; Rottey S
Acta Clin Belg; 2017 Feb; 72(1):24-28. PubMed ID: 28151378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
